Orphan drug market set to climb above $200B: Report
23 June 2017
Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as biopharma companies increasingly focus on meds to treat a variety of rare diseases. Sales for the super-pricey drug class will nearly double—again—by 2022 to $209 billion, according to a new industry analysis.
Pfizer scientists devise 2-pronged attack against blood cancers
23 June 2017
Most treatments for blood cancers like acute myeloid leukemia (AML) are designed to attack the cancer cells themselves. Now, scientists at Pfizer have figured out how to make those cells even more vulnerable to direct attack—by driving them from their favorite hiding place.
Worldwide drug sale forecasts fall as pricing pressures mount
22 June 2017
Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report on Tuesday.
Forget patient-centric models that don’t work. Let's talk social centricity, say researchers
22 June 2017
It’s time to move past patient centricity to social centricity. That was the message from inVentiv Health and GSW at Cannes Lions Health, where they presented the idea of a more holistic perspective.
The World Bank will support Indian biopharmaceutical industry
21 June 2017
The World Bank will support India in developing an innovative biopharmaceutical and medical devices industry, which is globally competitive and addresses the country’s major concerns around barriers to affordable healthcare.
Congress Struggles to Address Drug Prices
21 June 2017
Despite widespread public outrage over ever-rising outlays for prescription drugs, legislative action may be difficult to achieve. Senate and House leaders on both sides of the aisle have proposed numerous wide-ranging measures to tackle drug pricing issues, but none have sufficient support to move forward.
Early biotech financing healthy, but R&D productivity needs to look left field
20 June 2017
It’s the summer; it’s the BIO convention, and so too it’s time for Ernst & Young’s annual biotech health report, and when it comes to financing for early-stage biotechs and research spending, things are looking strong, although it’s a mixed bag across the whole sector.
Rospatent: two thirds of patents in pharmaceuticals are held by foreign companies
20 June 2017
Unlike other industries, two thirds of the total number of patents in pharmaceuticals are held by foreign companies. However, the practical activities of Rospatent are primarily aimed at protecting the interests of Russian citizens, who should receive only high-quality medicines that can resolve their problems.
The myth of “leaner and meaner” pharma
19 June 2017
Is pharma shedding employees to protect and grow the bottom line? Judging from the headlines, you might think so. But actually, instead of getting “leaner and meaner,” most big drug companies are getting fatter and softer — and a result, pharma’s human capital efficiency has been mostly stagnant.
Russia approved list of 96 bio-targets to develop the medicinal products analogues
16 June 2017
On June 8, 2016, the Russian Ministry of Justice registered the joint Order of the Ministry of Industry and Trade and the Ministry of Health of Russia “On Approval of the List of Bio-Targets for Developing the Analogues of Innovative Medicinal Products With Similar and Improved Pharmacotherapeutic Effect.” The list includes 96 items.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024